Work

Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2- metastatic breast cancer: A closer look at nonmedication expenses.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.1532

Authors: Asal Pilehvari, Wen You, Gretchen Genevieve Kimmick, Gloribel Bonilla, Roger Anderson

Institutions: University of Virginia Cancer Center, University of Virginia, Duke Medical Center, Duke Cancer Institute

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: American Cancer Society

Award: (Copy Of) Real-world patterns and impact of CDK4/6 inhibitor treatment of Metastatic Breast Cancer

OpenAlex ID: W4399324799

Cites:

Cited by: 3

Related to: 10